Журнал кардиореспираторных исследований 2026. №2/3

Тема статьи

Homilador ayollarda antifosfolipid sindromning kechish xususiyatlari (19-21)

Авторы

Z.B. Babamuradova, N.N. Shavazi

Учреждение

Samarqand davlat tibbiyot universiteti

Аннотация

Antifosfolipid sindromi (AFS) — bu akusherlik va trombotik asoratlar rivojlanishi bilan bog‘liq bo‘lgan autoimmun trombofilik holatdir. Mazkur maqolada ayrim revmatik kasalliklar fonida kechadigan homiladorlik holatlari, ayniqsa antifosfolipid sindromiga (AFS) alohida e’tibor qaratilgan holda tahlil qilingan. Homiladorlik natijalariga ta’sir etuvchi omillar, neonatal patologiyalar rivojlanishi o‘rganilib, ushbu toifadagi bemorlarda revmatik kasalliklarning ehtimoliy asoratlari xavfi baholangan. Homiladorlikni rejalashtirish va unga tayyorgarlik masalalariga alohida e’tibor qaratilgan. AFS bilan homilador ayollarni olib borish taktikasi hamda dori vositalarining dozalanish rejimi ko‘p jihatdan avvalgi anamnezga (platsentaga bog‘liq bo‘lmagan trombozlarning mavjudligi yoki yo‘qligi, spontan abortlar soni, avvalgi terapiya) bog‘liq. Shu sababli maqolada turli davolash turlariga ega klinik guruhlar ajratib ko‘rsatilgan. Ushbu ishning maqsadi — homilador ayollarda AFSning patogenezi, klinik ko‘rinishlari va kechish xususiyatlariga oid zamonaviy ma’lumotlarni tahlil qilishdir. Antifosfolipid antitanachalar mavjudligi homiladorlikni saqlab qolmaslik, platsentar yetishmovchilik, preeklampsiya va trombotik asoratlar xavfini sezilarli darajada oshirishi ko‘rsatilgan. Perinatal natijalarni yaxshilash uchun erta diagnostika va kompleks yondashuv muhimligi ta’kidlangan.

Ключевые слова

antifosfolipid sindromi, homiladorlik, homilani yo‘qotish, tromboz, preeklampsiya, platsentar yetishmovchilik.

Литературы

1. Miyakis S., Lockshin M.D., Atsumi T. et al. International consensus statement on an update of the classification criteria for define antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis, 2016, vol. 4, no. 2, pp. 295-306. 2. Tsirigotis P., Mantzios G., Pappa V. et al. Antiphospholipid syndrome: a predisposing factor for early onset HELLP syn- drome. Rheumatology International, 2017, vol. 28, no. 2, pp.171-174. 3. Gomez-Puerta J., Cervera R., Espinosa G. et al. Catastrophic antiphospholipid syndrome during pregnancy and puer-perium: maternal and fetal characteristics of 15 cases. Annals of the Rheumatic Diseases, 2017, vol. 66, no. 6, pp. 740-746. 4. Ruffatti A., Calligaro A., Hoxha A. et al. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care & Research, 2020, vol. 62, no. 3, pp. 302-307. 5. Boffa M.C., Lachassinne E. Infant perinatal thrombosis and antiphospholipid antibody: a review. Lupus, 2017, vol. 16, no. 8, pp. 634- 641. 6. Mekinian A., Lachassinne E., Nicaise-Roland P. et al. Euro- pean registry to babies born to mothers with antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2019, vol. 72, no. 2, pp. 217-222. 7. Lockshin M.D., Kim M., Laskin C.A. et al. Prediction of ad- verse pregnancy outcome by the presence of lupus anticoagu- lant, but not anticardiolipin antibody, in patients with an- tiphospholipid antibody. Arthritis & Rheumatology, 2019, vol. 64, no. 7, pp. 2311-2318. 8. Ruffatti A., Tonello M., Del Ross T. et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thrombosis and Haemostasis, 2016, vol. 96, no. 3, pp. 337-341. 9. Danowski A., de Azevedo M.N., de Souza Papi J.A. et al. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and antiphospholipid syndrome with systemic lupus erythematosus. Journal of Rheumatology, 2019, vol. 36, no. 6, pp. 1195-1199. 10. Gris J.C., Perneger T.V., Quere I. et al. Antiphosphol- ipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study. Blood, 2023, vol. 102, pp. 3504-3513. 11. Salmon J.E., Girardi G., Holers N.M. Activation of comple- ment mediates antiphospholipid antibody-induced pregnancy loss. Lupus, 2003, vol. 12, no. 7, pp. 535-538. 12. Cowchock F.S., Reece E.A., Balaban D. et al. Repeated fetal losses associated with antiphospholipid antibody: a collabora- tive randomized trial-comparing prednisone with low-dose heparin treatment. American Journal of Obstetrics and Gyne- cology, 2020, vol. 166, no. 5, pp. 1318-1323. 13. Rai R., Cohen H., Dave M. et al. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibody (or antiphospholipid antibody). British Medical Journal, 2021, vol. 314, pp. 253-256. 14. Kutteh W.H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. American Journal of Obstetrics and Gynecology, 2019, vol. 174, no. 5, pp. 1584-1589. 15. Ziakas P.D., Pavlou M., Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstetrics & Gynecol- ogy, 2020, vol. 115, no. 6, pp. 1256-1261. 16. Mak A., Cheung M.W., Cheak A.A. et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and posi- tive anti-phospholipid antibodies: a meta-analysis of random- ized controlled trials and meta- regression. Rheumatology, 2020, vol. 49, no. 2, pp. 281-288. 17. Fishman P., Falach-Vaknine E., Zigelman R. et al. Prevention of fetal loss in experimental anti-phospholipid syndrome by in vitro administration of recombinant Interleukin-3. Journal of Clinical Investigation, 2018, vol. 91, no. 4, pp. 1834-1837.